BioCardia
BCDA
20 hedge funds and large institutions have $12.3M invested in BioCardia in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
48% more call options, than puts
Call options by funds: $83K | Put options by funds: $56K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 1.27% → 1.23% (-0.04%)
9% less capital invested
Capital invested by funds: $13.5M → $12.3M (-$1.24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$674K |
| 2 |
BlackRock
New York
|
+$145K |
| 3 |
VF
Virtu Financial
New York
|
+$135K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
+$64.4K |
| 5 |
MFG
Magnus Financial Group
New York
|
+$60.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$822K |
| 2 |
Squarepoint
New York
|
-$204K |
| 3 |
EGM
Engineers Gate Manager
New York
|
-$95K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$76K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$74K |
BCDA Hedge Fund Activity: Q2 2021 in Review
20 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q2 2021, worth a combined $12.3M — down 9.1% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BCDA positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $674K. The largest seller was Renaissance Technologies, cutting an estimated $822K.
- 20 institutional investors held BioCardia (BCDA) as of Q2 2021, up from 19 in Q1 2021.
- Funds reported $12.3M of BioCardia stock for Q2 2021, down 9.1% quarter-over-quarter.
- 4 funds opened new BioCardia positions in Q2 2021 and 3 closed out, a net change of +1 holder.
- The largest BioCardia buyer in Q2 2021 was Vanguard Group, an estimated $674K added.
- The largest BioCardia seller in Q2 2021 was Renaissance Technologies, an estimated $822K sold.
Based on aggregated 13F filings for Q2 2021.